



Division: Pharmacy Policy	Subject: Prior Authorization Criteria
Original Development Date: Original Effective Date: Revision Date:	June 13, 2012; May 14, 2014, November 23, 2015

SENSIPAR® (cinacalcet)

LENGTH OF AUTHORIZATION: Up to one year

REVIEW CRITERIA:

- ❖ Age: ≥ 18 years of age (*Safety and efficacy not established in adolescent, children, and infants*)

One of the following diagnoses must be met:

- ❖ Secondary Hyperparathyroidism (HPT) due to Chronic Kidney Disease (CKD) and patient must be on dialysis
- ❖ Parathyroid Carcinoma resulting in hypercalcemia (elevated blood or serum calcium levels)
- ❖ Severe hypercalcemia in patients with primary HPT who are unable to undergo parathyroidectomy.

Secondary Hyperparathyroidism due to CKD (on dialysis)

- Initial dose: 30 mg by mouth (PO) once daily
- Titration is in sequential dosage increases every 2 to 4 weeks of 60, 90, 120 and 180 mg PO once daily.
- Max dose: 180 mg PO once daily

Parathyroid Carcinoma resulting in Hypercalcemia and Primary Hyperparathyroidism

- Initial dose: 30 mg PO twice daily (BID)
- Dose Titration: Titrate every 2 to 4 weeks – 60 mg PO BID, then 90 mg PO BID, then 90mg PO 3 to 4 times daily.
- Max dose: 360 mg / day PO

Dosage form and strength: 30mg, 60mg and 90mg tablets